Take a look at-Cap (CHEK) (~$12MM nano cap) is an Israeli primarily based clinical-stage scientific software corporate this is buying and selling smartly beneath money and not too long ago introduced that it employed Ladenburg Thalman (they have generated a couple of buzzy opposite mergers previously) to run a strategic choices procedure.  The corporate in the past was once creating a colon most cancers screening check however the ones efforts failed and along the strategic assessment announcement, Take a look at-Cap additionally introduced they’re shedding 90% in their body of workers, absolutely elevating the give up flag.

Working it thru a in reality fundamental liquidation research (it will have to be famous the corporate did not come with a liquidation within the listing of strategic selection choices, however somewhat they are taking a look at a sale, licensing settlement or opposite merger):

The severance prices for the 90% aid in power were not disclosed, in order that’s a wager, in conjunction with the G&A, however this one nonetheless trades at a large cut price to what it will distribute in a liquidation.  Now there are some pink flags, I do not see an important shareholder to offer protection to shareholder pursuits and the overseas corporate record and elevating cash within the U.S. chance is provide right here, despite the fact that now not completely unusual for biotech/bio scientific software firms to be primarily based in Israel.

Word it is a tiny corporate, do not use marketplace orders, however the cut price this is large sufficient for me so as to add a small place to my rising basket of damaged biotech liquidation applicants. 

Disclosure: I personal stocks of CHEK